Commentary|Podcasts|July 11, 2024
The Weight-Loss Gold Rush: Legal and Regulatory Implications
Author(s)Miranda Schmalfuhs
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Advertisement
Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:
- Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
- How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
- What needs to be done for GLP-1s to be covered
- Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
- Advice for investors and financiers who are considering entering the weight-loss medication market
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly to Submit Oral GLP-1 for FDA Priority Review Program: Report
2
GCC Emerges as a New Strategic Anchor for Global Venture Capital
3
Tylenol Maker Sued While Kennedy Says No ‘Sufficient’ Evidence for Autism Link
4
Pharmaceutical Executive Daily: Novo Nordisk's Unsolicited Acquisition Proposal
5
